RIVAL-05-06

RIVAL-05-06 refers to preclinical oncolytic virus candidates developed by Turnstone Biologics as part of their RIVAL (Rigorous Identification of Viral Assets for Lysis) platform. These candidates utilize a proprietary vaccinia virus backbone, specifically the SKV strain, which is engineered for potent tumor-selective replication and cell killing (oncolysis). The RIVAL platform is designed to overcome the limitations of earlier oncolytic viruses by enhancing systemic delivery and inducing a robust, multi-antigen anti-tumor immune response. While specific therapeutic payloads for RIVAL-05 and RIVAL-06 have not been publicly detailed in the provided context, the programs aim to treat various solid tumors by combining direct viral-mediated lysis with immune system activation.